Audentes Therapeutics will spend $109 million to build a gene therapy manufacturing plant in Sanford, N.C., the company said Feb. 18.
Audentes, a subsidiary of Astellas Pharma, said the 135,000-square-foot plant will create 200 jobs.
The first phase of construction will take place over the next 18 months, and the facility should be operational by next year, the drugmaker said.
Pfizer, AveXis, bluebird bio and Eli Lilly all have or are also building manufacturing sites in North Carolina, according to BioPharma Dive.
Read the full news release here.